Hypomelanotic Disorder Overview

Save information for later
Sign Up

Learn About Hypomelanotic Disorder

What is the definition of Hypomelanotic Disorder?
Hypomelanotic disorder is a term that refers to types of skin conditions in which melanocytes (pigment cells) have a loss of pigment. Types of hypomelanotic disorders include vitiligo, ash leaf spots, and idiopathic guttate hypomelanosis, among others.
What are the symptoms of Hypomelanotic Disorder?
Symptoms of hypomelanotic disorders include loss of pigmentation that varies by the type of disorder. Symptoms of vitiligo include a complete loss of pigment in the skin that appears as well-delineated spots and patches. Symptoms of ash leaf spots include oval flattened areas of skin that lack pigment and angiofibromas on the face. Symptoms of idiopathic guttate hypomelanosis include small white flattened areas on sun-exposed skin areas.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Hypomelanotic Disorder?
Treatment for hypomelanotic disorders depends on the type. Treatment for vitiligo may include corticosteroids, tacrolimus, pimecrolimus, ultraviolet B and PUVA therapy, self-tanning creams, and skin grafting. Treatment for ash leaf spots may include laser therapy. Treatment for idiopathis guttate hypomelanosis is not necessary.
Who are the top Hypomelanotic Disorder Local Doctors?
Experienced in Hypomelanotic Disorder
Dr. John M. Soderberg
Dermatology
Experienced in Hypomelanotic Disorder
Dr. John M. Soderberg
Dermatology

Forefront Dermatology Sc

3459 Old Halifax Rd, Suite I, 
South Boston, VA 
 (2.4 mi)
434-549-0383
Languages Spoken:
English, Swedish
See accepted insurances
Accepting New Patients
Offers Telehealth

John Soderberg is a Dermatologist in South Boston, Virginia. Dr. Soderberg and is rated as an Experienced provider by MediFind in the treatment of Hypomelanotic Disorder. His top areas of expertise are Plaque Psoriasis, Rosacea, Psoriasis, and Warts. Dr. Soderberg is currently accepting new patients.

Advanced in Hypomelanotic Disorder
Dr. Amy J. Mcmichael
Dermatology
Advanced in Hypomelanotic Disorder
Dr. Amy J. Mcmichael
Dermatology

Wake Forest University Health Sciences

1200 N Martin Luther King Jr Dr, 
Winston Salem, NC 
 (86.0 mi)
336-713-9800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amy Mcmichael is a Dermatologist in Winston Salem, North Carolina. Dr. Mcmichael and is rated as an Advanced provider by MediFind in the treatment of Hypomelanotic Disorder. Her top areas of expertise are Autosomal Recessive Hypotrichosis, Alopecia Areata, Graham-Little-Piccardi-Lassueur Syndrome, and GAPO Syndrome. Dr. Mcmichael is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Hypomelanotic Disorder
Dr. Erin B. Lesesky
Dermatology
Experienced in Hypomelanotic Disorder
Dr. Erin B. Lesesky
Dermatology

Duke Lightner Dermatology

11081 Forest Pines Dr, Suite 110, 
Raleigh, NC 
 (60.4 mi)
919-562-8887
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erin Lesesky is a Dermatologist in Raleigh, North Carolina. Dr. Lesesky and is rated as an Experienced provider by MediFind in the treatment of Hypomelanotic Disorder. Her top areas of expertise are Mycosis Fungoides, Basal Cell Skin Cancer, Extramammary Paget Disease, and Squamous Cell Skin Carcinoma. Dr. Lesesky is currently accepting new patients.

View All Doctors
What are the latest Hypomelanotic Disorder Clinical Trials?
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
Enrollment Status: Recruiting
Publish Date: February 21, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Enrollment Status: Recruiting
Publish Date: February 21, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

View All Clinical Trials